The full PDDS 2017 scientific program across 3 days — keynotes, oral presentations, and posters. Talks are ordered by program prominence within each day.
Day 1
- Keynote
Macrophage-stabilized drug crystals
Gus R. Rosania · University of Michigan College of Pharmacy, United States
Poorly soluble drugs with slow rates of clearance are poised to precipitate in the organism following long term oral administration. In this context, my research group has been characterizing the intracellular…
- Keynote
Engineered spatiotemporal delivery of morphogens for skeletal regeneration
Esmaiel Jabbari · University of South Carolina, United States
Osteogenesis and vascularization during bone development are coupled by spatiotemporal regulation of paracrine signaling in which the invading vascular endothelial cells secrete osteogenic morphogens to stimulate cell…
- Keynote
Transfection by cell-penetrating peptides
Ulo Langel · Stockholm University, Sweden
Recent data on mechanisms and applications of transfection strategies by cell penetrating peptides (CPP) are summarized on the variety of different oligonucleotide cargoes including plasmid, antisense and siRNA…
- Keynote
Bioinspired Sequence-defined drug, protein and gene carriers by chemical evolution
Ernst Wagner · Ludwig-Maximilians-Universitat Munich, Germany
Viruses and protein toxins present natural examples for potent intracellular delivery of nucleic acids or proteins. Natural evolution has optimized such carriers that comprise multiple different functions for overcoming…
- Keynote
Challenge and progress in delivering molecules to the brain
Teruna J. Siahaan · University of Kansas, United States
One of the major challenges in studying brain function and diseases (i.e., Alzheimer’s, Parkinson’s, multiple sclerosis (MS), and brain tumors) lies in the difficulty in delivering molecules to the brain. The critical…
- Oral · In-Person
Targeted self-navigating multifunctional drug delivery vehicles driven by promiscuous landscape phage proteins
Valery A. Petrenko · Auburn University, United States
Development of precision medicines acting specifically at the site of disease has been a long sought goal for the last century, starting from pioneering works of Paul Ehrlich, who suggested the concept of site-directed…
- Oral · In-Person
Nucleic acid based amphiphiles as soft materials for nanomedicine
Philippe Barthelemy · University of Bordeaux, France
The combination of nucleic acids chemistry (e.g., nucleoside, nucleotides, oligonucleotides) with supramolecular principles provides an efficient and powerful approach to prepare well-defined systems with tunable…
- Oral · In-Person
Patient centric dug delivery systems: ODT (Oral Disintegrating Tablet) and ODF (Oral Disintegrating Film)
Carmen Popescu · Roquette America, United States
Fast disintegration formulations like Oral Disintegrating Tablets (ODT) and Oral Disintegration Films (ODF) were emerging in the last decade due to the fact they offer patient convenience and compliance by fast…
- Oral · In-Person
Formulation of liposomal doxorubicin modified with Bombesin peptide for selective targeting of GRP receptors over-expressed by cancer cells
Giancarlo Morelli · University of Naples Federico II, Italy
The presentation concerns the obtainment of liposomal doxorubicin in which liposomes are externally modified with a targeting peptide able to drive liposomal doxorubicin in a selective way on membrane receptors over…
- Oral · In-Person
Development of receptor targeted nanocomplexes for delivery of RNA therapeutics to the lung
Stephen Hart · UCL GOS Institute of Child Health, United Kingdom
Cystic Fibrosis (CF) is caused by mutations in the cystic fibrosis transmembrane conductance regulator gene (CFTR), encoding a cyclic AMP-activated chloride channel. CFTR deficiency also regulates the epithelial sodium…
- Oral · In-Person
Drug delivery across the skin barrier using biocompatible thermoresponsive nanogels
Fiorenza Rancan · Charite - Universitatsmedizin Berlin, Germany
Several new therapeutic agents for the treatment of dermatological conditions are emerging. Despite skin accessibility, delivery of drugs across skin and maintenance of a sufficient drug concentration in the target…
- Oral · In-Person
Engineering endosomal escape using pHlexi particles
Georgina Kate Such · The University of Melbourne, Australia
The design of ‘smart’ delivery systems with tunable response to their environment is important for developing new therapies, as they allow efficient and controlled therapeutic release to a specific target site.…
- Oral · In-Person
Aptamers as therapeutic agents in human cancers and evidence for glioblastoma targeting through the blood-brain-barrier of aptamer-functionalized nanosystems
Laura Cerchia · Istituto per l’Endocrinologia e l’Oncologia Sperimentale “G. Salvatore” (IEOS), Italy
Highly selective compounds emerging for anti-cancer therapy are oligonucleotide aptamers that interact with their targets by recognizing a specific three-dimensional structure. Thanks to their unique properties (small…
- Oral · In-Person
Building a better antibody-based medicine: Antibody mimetic
Hanieh Khalili · University of East London, United Kingdom
Therapeutic proteins (e.g. monoclonal antibodies, cytokines, and enzymes) are widely used in healthcare. Monoclonal antibodies (particularly IgGs) are an important class of protein based-medicine which tend to aggregate…
- Oral · In-Person
Oral delivery of lipophilic drugs: The solubility-permeability interplay and formulation design
Arik Dahan · Ben-Gurion University of the Negev, Israel
Poor aqueous solubility is a major challenge in today’s biopharmaceutics. While solubility-enabling formulations can significantly increase the apparent solubility of the drug, the concomitant effect on the drug’s…
- Oral · In-Person
Inhalable therapy of pulmonary Tuberculosis mediated by polysaccharide microparticles
Ana Margarida Grenha · University of Algarve, Portugal
Tuberculosis remains a leading cause of death, although effective therapy is available for many years. Therapeutic failure is mainly due to non-compliance with prolonged treatments, often associated with severe…
Day 2
- Keynote
Driving endocytosis for enhancing cellular delivery and intracellular targeting of therapeutics
Arwyn T. Jones · Cardiff University, United Kingdom
Targeting disease processes inside cells with biopharmaceuticals represents a major challenge, not least in overcoming biological barriers such as those posed by the plasma membrane. Investment in this approach is…
- Keynote
Cyclodextrins as reliable solubilizationtools for BCS class II and IV drugs
Carmen Popescu · Roquette America, United States
In recent years, formulator’s attention was focusing on cyclodextrins as a solubilizing tool for their stubborn APIs (BCS class II and IV)). The reason is obvious: easy to scale up and a successful presence of APIs…
- Keynote
Dry powder inhalers - challenges and opportunities in delivering drugs to the lungs
El Hassane Larhrib · University of Huddersfield, United Kingdom
I will start my presentation by sharing with the audience the importance of particle engineering for different pharmaceutical applications such as oral and inhaled products. In the second part of my talk, I will stress…
- Keynote
Crystal engineering of alternative solid forms of therapeutic agents
Mino R. Caira · University of Cape Town, South Africa
The physicochemical properties and the performance of both active pharmaceutical ingredients (APIs) as well as new chemical entities (NCEs) can be significantly modified by converting them into different crystalline…
- Keynote
Anionophores, an emerging group of molecules to fight cancer
Ricardo Perez Tomas · University of Barcelona, Spain
Eukaryotic life is compartmentalized and the cells have membranes separating the interior from the outside environment. Similarly, the different organelles inside cells are enclosed by membrane. Correct ion exchange…
- Oral · In-Person
Lipoprotein based drug delivery platform
Andras G. Lacko · University of North Texas Health Science Center, United States
Although lipoprotein-based drug-delivery was proposed as an outstanding platform for diagnostic and therapeutic applications almost 35 years ago, no lipoprotein based formulations have so far reached the clinical trial…
- Oral · In-Person
Impact of surface anisotropic forces on powder flowability
Teresa Carvajal · Purdue University, United States
Powder flowability is essential upon handling and during the various unit operations used in the manufacturing of pharmaceutical products. Surface interactions such as cohesive- adhesive contribution depend on the…
- Oral · In-Person
Novel ring-fused tetrapyrrolic macrocycles as very active photodynamic agents for cancer
Teresa M. V. D. Pinho e Melo · University of Coimbra, Portugal
The research team has previously reported the synthesis of a new type of stable 4,5,6,7-tetrahydropyrazolo[1,5-a] pyridine-fused chlorins and bacteriochlorins via an [8π+2π] cycloaddition of diazafulveniummethides with…
- Oral · In-Person
Ex-vivo intraocular model to investigate long-term protein stability in vitreous humor
Sulabh Patel · F. Hoffmann-La Roche Ltd, Switzerland
Following intravitreal (IVT) injection of protein-loaded long acting delivery (LAD) system, therapeutic protein remains in vitreous humor (VH) and gets exposed at physiological pH and temperature for significantly…
- Oral · In-Person
Development of microparticles loaded with pine bark extracts and evaluation of its bioavailability on fish
Katherina Fernandez · University of Concepcion, Chile
Avoiding wounds in salmon and trout farming systems is an important need of the industry, due their potential production decline effect, caused by decrease of fish meat quality, and the consequent profits loss of the…
- Oral · In-Person
Can antibiotics treat cancer?
Rina Rosin-Arbesfeld · Tel-Aviv University, Israel
Colorectal cancer (CRC) is the third leading cause of cancer-related deaths in both men and women, with over 1 million people diagnosed each year. In around 85% of the people suffering from a precancerous condition…
- Oral · In-Person
Peptide-based therapeutics for the treatment of neurodegenerative diseases; challenges and opportunities
Eugenia V Gurevich · Vanderbilt University, United States
Arrestins were discovered as the key players in the desensitization of G protein-coupled receptors (GPCRs) by virtue of specific binding to active phosphorylated GPCRs and blocking further G protein activation. Both…
- Oral · In-Person
Polymer-based combination therapeutics
Maria J. Vicent · Polymer Therapeutics Lab, Spain
Polymer conjugates are nanosized hybrids that covalently combine a bioactive agent with a polymer to ensure not only its efficient release to the required intracellular compartment, but also its availability within a…
- Oral · In-Person
Hydrogen sulfide: A novel mediator and therapeutic target for inflammatory disease
Madhav Bhatia · University of Otago, New Zealand
Uncontrolled inflammation is responsible for several diseases, which are major health problems. Hydrogen sulfide (H2 S), a gas with the characteristic odour of rotten eggs, has been recognized as an important endogenous…
- Oral · In-Person
Locust Bean Gum-based nanoparticles for oral immunization
Luis Braz · University of Algarve, Portugal
During the presentation will be discussed the design of nanoparticles based on locust bean gum (LBG) and chitosan to be used as oral immunoadjuvant for vaccination purposes. The advantages of oral immunization and the…
- Oral · In-Person
Active loading of resveratrol in transferrin-functionalised liposomes using a pH gradient technique
Sarmad Al-Edresi · University of Manchester, United Kingdom
Resveratrol, a polyphenol, found in grapes and red wine, has been reported to have many potential therapeutic properties. However, resveratrol demonstrates poor water solubility and short biological half-life, and lacks…
- Oral · In-Person
Understanding intestinal permeability: The effect of intestine complexity on oral drug absorption
Arik Dahan · Ben-Gurion University of the Negev, Israel
I n this lecture, regional-dependent intestinal permeability will be discussed, including dissolution aspects, as well as pathophysiological conditions. Permeability is location dependent, and pertains to each point…
- Poster · In-Person
Oral delivery of a novel antibody domain (Vorabody™) for the treatment of Crohn’s Disease
John Wahlich · John Wahlich (VHsquared Ltd), United Kingdom
Only very few oral peptides have been commercialised to date, these include cyclosporin A (Neoral®) for the treatment of transplantation rejection; desmopressin (DDAVP®) for the treatment of nocturnal enuresis and…
- Poster · In-Person
Sustained and/or controlled delivery by core-shell polymer nanocapsules
Gemma Vilar · Leitat Tecnological Center, Spain
Nanoparticles are an important tool to overcome the administration of drugs, improving the pharmacokinetics of active compounds and avoiding their undesired effects. Specifically, nanoencapsulation offers some…
- Poster · In-Person
Development and evaluation of nanofibrous oral strips – new drug delivery system for poorly soluble drugs
Anna Kluk · Zentiva k.s, Czech Republic
Orodispersible films (ODFs) have recently gained much attention as a very beneficial formulation for pediatric and geriatric patients, where the difficulty of swallowing of the standard solid drug forms needs to be…
- Poster · In-Person
Absorption enhancing capacity of dissolving microneedle arrayed patches
Booyong Lee · Raphas Co., Ltd, Korea, Republic of
The microneedle-mediated transdermal delivery system has been developed to provide minimal invasive selfadministration method with patient friendly manner. Especially, dissolving microneedles, which deliver the target…
- Poster · In-Person
The effect of the inhalation manoeuvre parameters on the indacaterol drug deposition from OnbrezBreezhaler® dry powder inhaler.
Mohamad Abadelah · University of Huddersfield, United Kingdom
Dry powder inhalers (DPIs) have been traditionally developed based on in-vitro testing with a square-wave airflow profile as described in the Pharmacopoeia (USP, 2014). Several studies showed that the Pharmacopoeial…
- Poster · In-Person
The applications of potential aromatic prodrugs In NTR based cancer therapy
Tugba Gungor · Canakkale Onsekiz Mart University, Turkey
Nitroreductase enzymes catalyze the conversion of the nitro group of prodrug compounds via hydroxylamine to amine group and the active drug inhibits tumor formation by binding to DNA. E. coli NTR/CB1954…
- Poster · In-Person
A Pre-formulation study of recombinant human interleukins-1 receptor antagonist for emergency use
Amal Abukhares · University of Manchester, United Kingdom
Introduction: rhIL-1Ra is a recombinant form of the natural anti-inflammatory mediator, interleukin-1 receptor antagonist that competitively binds with type I receptors (IL-1RI). It inhibits effects of other…
- Poster · In-Person
Method indicative of stability for determination of rifaximin and its degradation products by thin chromatographic
Ana Carolina Kogawa · Univ Estadual Paulista – UNESP, Brazil
Rifaximin is an oral antimicrobial, intestine-selective and non systemic with adverse effects compared to placebo. Rifaximin, until then, does not have standardized analytical methods in most official compendia. Fast…
- Poster · In-Person
Design and synthesis of new EF2K inhibitors for the treatment of TNBC and pancreatic cancers and their in vitro release studies from biocompatible natural polymeric particles
Ferah Comert Onder · Canakkale Onsekiz Mart University, Turkey
Triple-negative breast cancer (TNBC) and pancreatic cancers are aggressive malignancies that respond poorly to treatments and is associated with high rates patient deaths despite surgery and adjuvant chemotherapy. With…
- Poster · In-Person
Polyphenols loaded vaginal microbicide: A novel strategy for prevention of HIV transmission
Amit Mirani · Institute of Chemical Technology, India
The unprotected sexual intercourse associated HIV is one of the most serious challenges to public health all over the world. According to recent reports, sexual transmission is the predominant mode of HIV transmission.…
- Poster · In-Person
Nanoparticle Engineering of atovaquone using nano-by-design (NbD) approach
Pratik S. Kakade · Institute of Chemical Technology, India
One of the major problems of poorly soluble drugs is low bioavailability. The problem is basically related with BCS class II drugs which are poorly soluble in both aqueous and nonaqueous media. Atovaquone (ATQ), a BCS…
- Poster · In-Person
Analytical method development and validation of End-LAA for in vitro and in vivo studies
Cansel Kose Ozkan · Gulhane Education and Research Hospital, University of Health Sciences, Turkey
Endomorphin-1 is more effective in the treatment of neuropathic pain than morphine-like analgesics and side effects after treatment are less due to its endogenous nature. However, endomorphin-1 cannot be clinically used…
Day 3
- Keynote
Nanocomposite microparticles for the pulmonary delivery of bio-macromolecules
Gillian Hutcheon · Liverpool John Moores University, United Kingdom
The development of new biopharmaceutical therapeutics including proteins, peptides, vaccines, antibodies and nucleic acids is steadily increasing presenting new opportunities for the treatment and prevention of disease.…
- Keynote
Development of nitroreductase/prodrug system for cancer therapy
Mehmet Ay · Canakkale Onsekiz Mart University, Turkey
Conversion of an inactive drug (prodrug) into an active drug is the starting point of the Enzyme Prodrug Therapy (EPT), one of the novel strategies attracted attention increasingly over 20 years to develop new solutions…
- Keynote
Comparison of UV, IR, CE, HPLC and turbidimetric methods in the evaluation of rifaximin
Ana Carolina Kogawa · Univ Estadual Paulista – UNESP, Brazil
An adequate analytical method can be the first step in the rational use of pharmaceuticals. Currently, however, the effectiveness of the method of analysis is not enough. It should also be environmentally friendly…
- Oral · In-Person
INN Darunavir. Patenting problem of active pharmaceutical substances
Mikhail Samuilovich Goizman · Drugs Technology LLC, Russian Federation
One of the best HIV-protease inhibitors is [(3R,3?S,6?R)-hexahydrofuro[2,3-b]furan-3-ol](1S,2R)-3-[[(4-aminophenyl) sulphonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropyl]carbamate (I) (INN Darunavir). PREZISTA and…
- Oral · In-Person
Preclinical development of GMC1, a novel molecule targeting FKBP52 for the treatment of castration resistance prostate cancer
Huan Xie · Texas Southern University, United States
Purpose: GMC1 directly inhibits FKBP52, effectively blocking androgen receptor dependent gene expression and androgenstimulated proliferation. This makes it an attractive option for the treatment of hormone-dependent…
- Oral · In-Person
Development of formulations for novel chemotherapeutic agents for Tuberculosis and HIV coinfection
Omonike A. Olaleye · Texas Southern University, United States
Background: Human immunodeficiency virus (HIV) has changed the global profile of Mycobacterium tuberculosis (Mtb), the causative agent of tuberculosis (TB). TB is the leading cause of death in AIDS patients worldwide.…
- Oral · In-Person
Steroid estrogen analogues as potential drugs with targeted action
Svetlana N. Morozkina · ITMO University, Russian Federation
Steroid estrogens being sex female hormones play crucial role in the functioning of male and female organisms. After menopause, the estrogen level is tragically decreased that causes many disorders like osteoporosis…
- Oral · In-Person
The bone-cartilage interface: A complex biological barrier with potential therapeutical targets
Elod Erno Nagy · University of Medicine and Pharmacy Targu-Mures, Romania
The crosstalk of cartilage and subchondral bone is thought to be a central process in the regulatory pathways of osteoarthritis (OA). Histological changes in OA comprise degeneration and decellularization of the…
- Oral · In-Person
Improvements of computational optimization of drug-target interactions
Csaba Heteny · University of Pecs, Hungary
Optimization of drug-target interactions is a central issue of structure-based drug design. There are fast docking methods available for calculation of the structure and energy of target-ligand complexes. Docking is the…
- Oral · In-Person
Towards improved activity and stability of gene therapeutics
Kira Astakhova · University of Southern Denmark, Denmark
The main topic that I will discuss is the synthesis of novel peptide-oligonucleotide conjugates (POCs) and evaluation of their therapeutic potential. Our recent data shows that internally labelled POCs (shown in Chart…
- Oral · In-Person
Smart lipid nanocarriers: Potential for intracellular targeting
Vandana B. Patravale · Institute of Chemical Technology, India
Intracellular delivery of anticancer drugs and therapeutic genes (DNA, siRNA, shRNA etc.) is a challenging task faced by pharmaceutical formulators necessitating the need for effective strategies which facilitate…
- Oral · In-Person
Potentiation of cytotoxic action of the new cisplatin derivative by UV irradiation
Jitka Pracharova · Palacky University, Czech Republic
Platinum complexes such as cisplatin [cis-diamminedichloridoplatinum(II)] and its analogues are widely used as very effective chemotherapeutic agents. The anticancer activity of these drugs is related to the hydrolytic…
- Oral · In-Person
Impact of gut microbiota-mediated bile acid metabolism on the solubilization capacity of bile salt micelles and drug biopharmaceutical properties
Elaine F. Enright · University College Cork, Ireland
The symbiotic cohabitation of man and microbe has gained increasing recognition as a determinant of the health status of the human host, affording new insights into disease pathogenesis, as well as novel therapeutic…
- Oral · In-Person
Development of intravenous form of rifapentine and its in vivo evaluation
Konstantin Ostrovskiy · Drugs Technology LLC, Russian Federation
Rifapentine is a semisynthetic rifamycin antibiotic highly active against a broad spectrum of microorganisms including Mycobacterium tuberculosis. Rifapentine solubility in water is very low (0.1 mg/ml); therefore, its…
- Oral · In-Person
Green technology approach for development of BCS Class II molecule nanoformulation
Sandip Gite · Institute of Chemical Technology, India
Fenofibrate (FNB), a BCS class II molecule is primarily used in hypercholesterolemia and hypertriglyceridemia. FNB presents a poor bioavailability of 36% due to its low solubility. To overcome the issue of solubility…
Present your research at PDDS 2027
Abstract submissions for the 2027 program are open · September 13–15, 2027 · Olympia Hotel, Events & Spa, Valencia, Spain.
Join the PDDS 2027 delegation
Valencia · September 13–15, 2027 · Hybrid · in-person & virtual
Attend without presenting.